Funding in the bio-pharma sector continues to face uncertainties and inconsistencies, with factors such as taxes, regulatory changes, and interest rates playing significant roles. Nandini Piramal, Chairperson of Piramal Pharma, sheds light on the challenges faced by Contract Development and Manufacturing Organisations (CDMO) amidst a backdrop of evolving funding landscapes. Discussing the company’s financial performance in Q1 of 2025, Piramal emphasizes the impact of external factors on revenue and expansion plans.
Despite a dip in the CDMO business, Piramal Pharma remains focused on capacity expansion, allocating a substantial amount for growth initiatives. With a network spanning the US, UK, and India, the company’s strategic investments aim to bolster its position in the industry. Beyond financial figures, Piramal delves into the intricacies of destocking and market dynamics, providing a comprehensive view of Piramal Pharma’s operations. Looking ahead, Piramal expresses optimism for the company’s trajectory, highlighting growth prospects in various segments and outlining ambitious revenue targets for the future.
Read more from thehindubusinessline.com